Volume 392, Issue 10162, Pages 2353-2366 (December 2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Christopher C Parker, MD, Prof Nicholas D James, PhD, Christopher D Brawley, MSc, Prof Noel W Clarke, ChM, Alex P Hoyle, MRCS, Adnan Ali, MBBS, Alastair W S Ritchie, MD, Prof Gerhardt Attard, MD, Simon Chowdhury, PhD, William Cross, PhD, Prof David P Dearnaley, FRCR, Prof Silke Gillessen, MD, Clare Gilson, MRCP, Prof Robert J Jones, PhD, Prof Ruth E Langley, PhD, Zafar I Malik, FRCR, Prof Malcolm D Mason, MD, David Matheson, PhD, Robin Millman, J Martin Russell, MBChB, Prof George N Thalmann, MD, Claire L Amos, PhD, Roberto Alonzi, MD, Amit Bahl, FRCP, Alison Birtle, FRCR, Omar Din, MD, Hassan Douis, PhD, Chinnamani Eswar, FRCR, Joanna Gale, FRCP, Melissa R Gannon, MSc, Sai Jonnada, FRCR, Sara Khaksar, FRCR, Jason F Lester, FRCR, Prof Joe M O'Sullivan, MD, Omi A Parikh, FRCR, Ian D Pedley, MBChB, Delia M Pudney, MBChB, Denise J Sheehan, FRCR, Narayanan Nair Srihari, FRCR, Anna T H Tran, FRCR, Prof Mahesh K B Parmar, DPhil, Matthew R Sydes, MSc The Lancet Volume 392, Issue 10162, Pages 2353-2366 (December 2018) DOI: 10.1016/S0140-6736(18)32486-3 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Trial profile The Lancet 2018 392, 2353-2366DOI: (10.1016/S0140-6736(18)32486-3) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Overall survival and failure-free survival, by treatment HR=hazard ratio. Solid lines show the Kaplan-Meier analysis and dotted lines show the flexible parametric model. The Lancet 2018 392, 2353-2366DOI: (10.1016/S0140-6736(18)32486-3) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 3 Treatment effect on overall survival within selected baseline categories HR=hazard ratio. PSA before androgen deprivation therapy (continuous), p=0·029; effect of adding radiotherapy is smaller with higher PSA. Patients with unknown T stage (TX), unknown N category (NX), or unknown Gleason sum score are not presented in the forest plot and do not contribute to interaction test results. Dotted line shows the overall hazard ratio. (A) Prespecified subgroup analyses. (B) Exploratory subgroup analyses. The Lancet 2018 392, 2353-2366DOI: (10.1016/S0140-6736(18)32486-3) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 4 Overall survival and failure-free survival by treatment and metastatic burden HR=hazard ratio. Solid lines show the Kaplan-Meier analysis and dotted lines show the flexible parametric model. The Lancet 2018 392, 2353-2366DOI: (10.1016/S0140-6736(18)32486-3) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 5 Time from randomisation to life-prolonging therapy The Lancet 2018 392, 2353-2366DOI: (10.1016/S0140-6736(18)32486-3) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions